Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis
Translational lung cancer research, pp. 188-203, 2020.
PD-1/L1 inhibitorsfront-linenetwork meta-analysis (NMA)non-small cell lung cancer (NSCLC)
We conducted a systematic comparison of first line immunotherapy for advanced NSCLC. Chemo-immunotherapies were better than chemotherapy and mono-immunotherapies in most patients. Pembrolizumab might have better efficacy than other PD-1/L1 inhibitors.
Full Text (Upload PDF)
PPT (Upload PPT)